Ressources
Recherchez un centre participant à l’essai clinique AIRFLOW-3 ou recevez les dernières nouvelles sur Nuvaira et les mises à jour multimédia.
Rechercher un centre investigateur
Recherchez un centre près de chez vous qui dispose du traitement par le système de dénervation des poumons dNerva dans le cadre de l’essai clinique AIRFLOW-3.
Centres investigateurs en Europe
Centres investigateurs en États-Unis
Contactez-nous pour en savoir plus sur le processus d’orientation des patients
Actualités et médias
Jan 25, 2022
200th Treatment Milestone for AIRFLOW-3 COPD Trial
300 Patients Treated Worldwide with dNerva® Targeted Lung Denervation therapy MINNEAPOLIS, January 25, 2022 – Nuvaira, a developer of novel therapeutic strategies…
Août 11, 2021
Nuvaira Announces AIRFLOW-3 COPD Pivotal Trial Milestone
Nuvaira Announces AIRFLOW-3 COPD Pivotal Trial Milestone 100 Randomized Patients; Inspire’s CEO Tim Herbert appointed Chairman of the Board MINNEAPOLIS, August…
Nov 23, 2020
Nuvaira Announces Published Two-Year Results in COPD Patients treated with Targeted Lung Denervation
AIRFLOW-2 two-year data confirm sustained reduction of severe COPD exacerbation risk vs. a control group. MINNEAPOLIS, Nov. 23, 2020 /PRNewswire/ — Nuvaira, a…
Juin 08, 2020
Nuvaira Announces FDA Breakthrough Designation for AIRFLOW-3 Pivotal Trial Device
Inspire Medical Systems CEO Tim Herbert has joined Nuvaira Board of Directors MINNEAPOLIS, June 8, 2020 – Nuvaira, a developer of novel therapeutic strategies…
Fév 04, 2020
Nuvaira Announces Chief Financial Officer and Pivotal Study Milestone
Seasoned Veteran Tom Griffin Joins Nuvaira’s Executive Team MINNEAPOLIS, Feb. 4, 2020 – Nuvaira, a developer of novel therapeutic strategies to treat obstructive…
Août 19, 2019
Nuvaira Announces Peer-Reviewed Publications of Targeted Lung Denervation Mechanisms of Action and Clinical Outcomes
AIRFLOW-2 randomized, sham-controlled one-year data accepted by AJRCCM MINNEAPOLIS, Aug 19, 2019 – Nuvaira, a developer of novel therapeutic strategies to…